Nan Fung Trinity’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nan Fung Trinity’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-217,014	Closed	-$18M	–	21
2022 Q2	$18M	Sell	217,014 -63,400	-23%	-$5.05M	5%	9
2022 Q1	$21.6M	Buy	280,414 +24,600	+10%	+$2.06M	4.13%	10
2021 Q4	$22.6M	Hold	255,814	–	–	4.91%	10
2021 Q3	$19.8M	Hold	255,814	–	–	4.7%	8
2021 Q2	$21.3M	Buy	255,814 +25,900	+11%	+$2.05M	4.47%	10
2021 Q1	$17.4M	Buy	229,914 +68,500	+42%	+$5.6M	3.82%	10
2020 Q4	$14.2M	Buy	161,414 +25,500	+19%	+$2.02M	2.51%	13
2020 Q3	$10.3M	Buy	135,914 +58,150	+75%	+$5.88M	2.09%	13
2020 Q2	$9.59M	Hold	77,764	–	–	2.13%	15
2020 Q1	$6.57M	Hold	77,764	–	–	1.94%	17
2019 Q4	$6.57M	Buy	+77,764	New	+$5.87M	1.26%	20

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nan Fung Trinity's BMRN Position: Q3 2022 in Review

Nan Fung Trinity sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 217,014 shares — an estimated $18M sold.

Nan Fung Trinity first reported a position in BMRN in Q4 2019 and held it in 11 quarters. The position peaked at $22.6M in Q4 2021. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Nan Fung Trinity reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Nan Fung Trinity sold 217,014 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $18M.
Nan Fung Trinity first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Nan Fung Trinity's BioMarin Pharmaceuticals position peaked at $22.6M in Q4 2021.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Nan Fung Trinity's 13F filing for Q3 2022, filed 26 Oct 2022.